

## **Approach to Anemia**

Tzu-Fei Wang, MD
Assistant Professor
Department of Internal Medicine
Division of Hematology
The Ohio State University Wexner Medical Center



## **Laboratory Evaluation of Anemia**

- Complete blood count (including MCV)
- · Peripheral blood smear
- Reticulocyte count
  - · Relative reticulocyte count
    - Percent of all RBC (normal 0.8%-1.5%)
  - · Absolute reticulocyte count
    - Relative reticulocyte count x RBC count
    - Normal 50,000-75,000/µl
- Other workup depending on the suspected causes (i.e. nutritional deficiency, hemolysis, etc)



# Anemia with low/normal reticulocyte count

- Low MCV (microcytosis)
  - Iron deficiency
  - · Anemia of chronic disease
  - · Lead intoxication
  - · Sideroblastic anemia
- Normal MCV
  - · Anemia of chronic kidney disease
  - Medications
  - Infections
- High MCV (macrocytosis)
  - Vitamin B12 and/or folate deficiency
  - Medications
  - · Liver disease, ETOH
  - Thyroid disease

## Iron Intake

- Mean iron intake 10-15 mg/d
- Main source of iron intake is meat (especially red meat)
- Serum iron is NOT a marker of iron status (will change with even just one meal)



Fairweather-Tait S.; Proc Nutrition Society, 200;63:519-528

## **Body Iron Distribution and Storage**

- Duodenum absorption: ~1-2 mg a day
- Iron loss (sloughed mucosal cells, menstruation, other blood loss): ~1-2 mg a day
- · Total body iron storage: 3000-4000 mg
  - · Plasma transferrin: 3 mg
  - Muscle (myoglobin): 300-500 mg
  - Bone marrow: 300 mg
  - Reticuloendothelial macrophages: 600 mg
  - Circulating erythrocytes (Hgb): 1800-2500 mg
  - · Liver (storage iron as ferritin): 1000 mg

Andrews, NC. N Engl J Med 1999;341:1986-1995

## **Causes of Iron Deficiency in Adults**

Iron deficiency is a symptom, not a disease

- A world-wide problem
- 3% of toddlers age 1-2 years
- Up to 10% of women of child bearing age
- Increased iron requirements
  - Blood loss
    - Gastrointestinal tract
    - · Menstrual periods
    - Blood donation
  - Pregnancy and lactation
- Inadequate iron supply
  - Insufficient dietary iron
  - Impaired iron absorption
    - · Gastric (bariatric) surgery
    - · Atrophic gastritis
    - Intestinal malabsorption
    - Celiac disease
    - H. pylori infection

#### **Neurologic syndromes** associated with iron deficiency


- Pica
  - Latin word for magpie, a bird which is reputed to eat almost anything
  - **Definition: Compulsive** ingestion of a non-food substance such as starch, clay, earth, ice
  - Ceases within days of therapy
  - Occurs in ~25% of patients with iron deficiency anemia from any cause
  - More commonly in women

- Restless leg syndrome
  - Common neurologic disorder
  - Criteria for diagnosis:
    - An urge to move the legs usually accompanied by uncomfortable
    - sensations Sensation begins or worsens during periods of rest
    - Sensations relieved by
    - movement Worse in the
  - evening/night
    Occurs in ~10% of cases of iron deficiency anemia


#### **Diagnosis of Iron Deficiency**

- **Laboratory Tests** 
  - Serum ferritin is the best value for iron deficiency (< 20 ug/L diagnostic of Fe deficiency anemia)
    MCV- the second most reliable indicator of iron stores

  - TIBC- high in iron deficiency and low in ACD
  - Serum iron/iron saturation
    - · Doesn't differentiate between iron deficiency and anemia of inflammation
- Peripheral blood smear



Ed Uthman from Houston, TX, USA (CC BY 2.0)



#### **Treatment With Iron: Principles**

- Iron is absorbed best on an empty stomach
- Ascorbic acid increases absorption and toxicity
- Reticulocytosis occurs <7days; Increased</li> Hgb in 2-3 weeks
- Maximum iron dose ~200 mg/day
- Side effects: Gl upset, constipation, black stool
- Encourage iron rich food

## **Available Oral Iron Supplements**

Oral iron preparations	Typical dose (mg)	Elemental iron (mg)	Approx. cost to give 5000 mg
Ferrous sulfate (also has elixir version)	325 mg tid	65	\$10.00
Ferrous gluconate	300 mg tid	36	\$7-8.00
Ferrous fumarate	100 mg tid	33	\$8.00-9.50
Iron polysaccharide complex	150 mg bid	150	\$11.00
Carbonyl iron	50 mg tid	50	\$18.00

### Inadequate Response to Oral Iron

- Intolerance/Noncompliance (~30% discontinue)
- Persistent blood loss
- Decreased iron absorption
- Chronic inflammation or bone marrow damage
- Chronic kidney disease

## **IV Iron Agents**

- Iron Dextran
  - INFeD®
  - Dexferrum<sup>®</sup>
- Sodium ferric gluconate complex (SFGC)
  - Ferrlecit<sup>®</sup>
- Iron Sucrose
  - Venofer<sup>®</sup>
- Ferumoxytol
  - Feraheme™

#### **Anemia of Chronic Disease**


- Characteristics
  - ◆ Immune-driven by inflammatory cytokines

    ◆ Diversion of iron into RF system (iron not in the "ri
  - $\bullet$  Diversion of iron into RE system (iron not in the "right place"
  - ◆Blunted erythropoietin response
- Diagnosis- iron status

Parameter	Anemia of Chronic Disease	Iron deficiency anemia
Serum Iron	Reduced	Reduced
TIBC	Reduced-Normal	Increased
% saturation (TSAT)	Reduced	Reduced
Ferritin	Normal-increased	Reduced
sTfR	Normal	Increased
Cytokine levels	Increased	Normal

#### **Anemia of Chronic Disease**

 Impaired iron transfer from reticuloendothelial macrophages and duodenum to plasma transferrin, then to liver



http://www.uptodate.com/contents/causes-and-diagnosis-of-iron-deficiency-anemia-in-the adult?topicKey=HEME%2F7150&elapsedTimeMs=0&view=print&displayedView=full

# Treatment Options for Anemia of Chronic Disease

- Treat the underlying diseases
- RBC Transfusions
- For anemia of chronic kidney disease:
  - Erythroid-stimulating agents (ESA) and potentially iron supplementation (ferritin <100 and/or iron sat <20%)</li>
- For selected cases of anemia related to cancer or myelodysplatic syndrome
  - Consider ESA

#### **Megaloblastic Anemia**

- · Defect in DNA synthesis
- · RNA synthesis is relatively unimpaired
  - RBC's hemoglobin production is far ahead of nuclear maturation
  - Nuclear cytoplasmic dissociation
- Ineffective erythropoesis
  - · Intramedullary hemolysis
  - Decreased red cell survival/misshapen cells

#### Vitamin B12 and folate

#### Vitamin B12

- Sources: dietary meat products
- Daily requirement 2-5 ug/day
- Total body stores 2-4 mg
- If intake stops, takes 2-3 years for storage to be depleted

#### **Folate**

- Sources: green leafy vegetables
- Daily requirement about 50-100 ug/day
- Total body reserves (5-10 mg) last only 3-4 months
- Heat labile and water soluble
- Absorbed in jejenum and ileum

#### Signs/Symptoms of B12 Deficiency

- · Anemia, hypersegmented neutrophils
- "Beefy Red" tongue, smooth surface of the tongue
- Neurologic
  - demyelination of the posterior and lateral columns of the spinal cord
  - paresthesia, loss of position/vibratory sense
  - in advanced disease, neuropathy, muscle weakness, and even CNS symptoms (irritability, somnolence, psychosis)



Wikipedia, https://en.wikipedia.org/wiki/Hypersegmented\_neutrophil

#### **Bone marrow process**

- · Broad DDx, including
  - · Acute or chronic leukemia
  - · Myelodysplatic syndrome (MDS)
  - Myeloproliferative diseases (MPD)
  - · Involvement of malignancies in the bone marrow
  - · Disseminated infections in the bone marrow
- Patients usually have more symptoms such as unexplained weight loss, petechiae, fever, hepatosplenomegaly, etc
- More than one cell line is abnormal and could be savera
- Referral to hematology and bone marrow biopsy is needed for definitive diagnosis

http://www.uptodate.com/contents/evaluation-of-bone-marrow-aspiratesmears?topicKey=HEME%2F4434&elapsedTimeMs=0&source=search\_result&searchTerm=I eukemia+bone+marrow&selectedTitle=1%7E150&view=print&displayedView=full

## **Approach to Anemia**

Payal Desai, MD
Assistant Professor
Director of Sickle Cell Research
Division of Hematology
The Ohio State University Wexner Medical Center

# Classification of Inherited Diseases of Hemoglobin

- Production abnormalities (Thalassemias)
- Structural abnormalities (Hemoglobinopathies)

#### Alpha-thalassemia Main mechanism is whole gene deletion: αα/αα Normal Silent carrier -α/α.α. SE Asia, 28% African Americans. Normal or slightly ↓MCV; ± HbH inclusions α-thalassemia minor -α/-α SE Asia, 3% of Black Americans, Mediterranean --/αα \_\_ No clinical disease No or mild anemia, ↓MCV, target cells HbH inclusions may be seen Genetic counseling

#### Beta-thalassemia

- · Hypochromic, microcytic anemia
- · Variants Major, Intermedia, Minor
- ↑ WBC, normal platelet count
- Iron studies ↑ serum Fe, transferrin saturation and ferritin
- · Bone marrow erythroid hyperplasia
- Hemoglobin electrophoresis
  - Minor elevated HbA2
  - · Only HbF and HbA2 are present
  - · Variable amounts of HbA if transfused

#### Anemia with high reticulocyte count


- Low MCV (microcytosis)
  - Hemoglobinopathies (such as some sickle cell)
- Normal/High MCV
  - · Acute hemorrhage
  - · Hemolytic Anemia
    - Hemoglobinopathies
    - · Membranopathies/enzymopathies
    - Autoimmune
    - Microangiopathic Hemolytic Anemia

# **Unstable Hemoglobins**

- Rare disorders. Many variants described
- Autosomal dominant only heterozygotes exist (homozygous do not survive)
  - Disrupt contact between heme and globin
  - Alter amino acids at interface between  $\alpha$  and  $\beta$  chains
  - Alter the shape or structure of the globin molecule

# **Unstable Hemoglobins**

Denaturation and precipitation of globin chains in RBC's →
Heinz bodies which cling to membrane → removed in spleen →
hemolysis





The Common Variants of Sickle Cell Disease				
Genotype	Percent			
β <sup>s</sup> -β <sup>s</sup>	65			
$\beta^s$ - $\beta^c$	24			
β <sup>s</sup> - β <sup>+</sup> thal	7			
β <sup>s</sup> - β° thal	3			
	$\beta^{S}$ - $\beta^{S}$ $\beta^{S}$ - $\beta^{C}$ $\beta^{S}$ - $\beta^{+}$ thal			

# Sickle Cell Anemia Pathophysiology

- · Manifestations of SCD are driven by:
  - Vaso-occlusion with ischemiareperfusion injury
  - · Hemolytic anemia
  - Endothelial Activation


Owusu-Ansah 2015

# **Mortality in Sickle Cell Disease**

#### Childhood mortality rates in SCD

- In 1973 median survival of 14.3 years
- CSSCD ~ 85% SS children and adolescents with survived to age 20
- In 2004 survival analysis of SS and Sβ° subjects SCD-related survival 93.6% by age 18

Diggs LM. Anatomic lesions in sickle cell disease. Sickle cell disease: diagnosis, management, education, and research. St. Louis: C.V. Mosby, 1973:188-229 Leikin SL, Gallagher D, Kinney TR, Sloane D, Klug P, Rida W. Mortality in children and adolescents with sickle cell disease. Pediatrics 1989;84:500-508 Platt et al. Mortality In Sickle Cell Disease – Life Expectancy and Risk Factors for Early Death. N Engl J Med 1994; 330:1639-1644 Quinn C T et al. Survival of Children with Sickle Cell Disease. Blood 2004;103:4023-4027



## **Immune Hemolytic Anemias**

- Autoimmune
  - · Warm antibody-mediated
  - Cold antibody-mediated
  - Paroxysmal Cold Hemoglobinuria
- · Drug-related hemolysis
- Hemolytic transfusion reactions
- · Hemolytic disease of the newborn
- Paroxysmal Nocturnal Hemoglobinuria

## **Auto-Immune Hemolytic Anemias**

- Antibodies causing hemolysis can be broken down into 2 general categories: warm and cold
- Warm antibodies react with RBCs best at 37° and typically do not agglutinate red cells
- Cold antibodies typically react best at <32° and do cause RBC agglutination

## Coomb's Test

- The Direct Coomb's = DAT (Direct Antiglobulin Test) - tests for IgG or C3 DIRECTLY ON THE RED CELLS.
- The Indirect Coomb's tests for IgG or C3 in the serum which react with generic normal red cells. This is also known as the antibody screen in blood-banking.

# Warm-Antibody Hemolytic Anemias Etiology

- Primary or Secondary
  - Drugs
  - · Solid or hematologic malignancy
  - · Infection
  - · Collagen Disease
  - Pregnancy
- Can be associated with immune platelet destruction = Evan's syndrome

# Warm-Antibody Hemolytic Anemias Clinical Features

- · Splenomegaly, jaundice is usually present
- Depending on degree of anemia and <u>rate of fall</u> in hemoglobin, patients can have VERY symptomatic anemia
- · Lab Dx -
  - ↑reticulocytes, ↑ bili, ↑ LDH, ↓haptoglobin
  - · Positive Coomb's test both direct and indirect
  - · Spherocytes are seen on the peripheral smear

#### Warm-Antibody Hemolytic Anemias Treatment

- Patients may require red cell transfusions, if they are symptomatic with their anemia
- However, immunosuppression is the mainstay of therapy
- First Line Steroids
  - 1mg/kg/d prednisone oral or methlyprednisolone IV
  - Continue until Hb > 10g/dL then taper
  - Continue with Vitamin D, Ca, + bisphosphonates
  - Consider PCP prophylaxis
  - Supplement with Folic Acid

Lechner et al. How I Treat Autoimmne Hemolytic Anemia. Blood 2010. Crowther et al. Evidence-based focused review of the treatment of idiopathic warm immune hemolytic anemia in adults. Blood 2011

## **WAIHA: Treatment**

- Second Line Therapy
  - 80% patient with CR or PR with prednisone
  - 15-20% need higher than maintenance dose to stay in remission
  - <20% of patients stay in remission after withdrawal of steroids

Lechner et al. How I Treat Autoimmne Hemolytic Anemia. Blood 2010. Crowther et al. Evidence-based focused review of the treatment of idiopathic warm immune hemolytic anemia in adults. Blood 2011

## **WAIHA: Treatment**

- 2<sup>nd</sup> Line Therapy
  - Splenectomy
  - Rituxan
- Other Therapies
  - Danazol
  - · Cyclophosphamide
  - · Cyclophosphamide
  - Mycophenolate Mofetil
  - Cyclosporine
  - Vincristine
  - Alemtuzumab
  - Ofatumumab

- Ineffective therapies
  - Azathioprine
  - BMT
  - IVIG
  - Plasma Exchange

Lechner et al. How I Treat Autoimmne Hemolytic Anemia. Blood 2010.

Crowther et al. Evidence-based focused review of the treatment of idiopathic warm immune hemolytic anemia in adults. Blood 2011

#### Drug-Induced Immune Hemolysis Three general mechanisms


- · Innocent bystander
  - · Quinine, Quinidine, Isoniazide
- Hapten
  - · Penicillins, Cephalosporins
- True autoimmune
  - Alpha-methyldopa, L-DOPA, Procainamide

Mechanism	DAT	Serum and Eluate	
Neoantigen -Drug +RBC complex	C3 (sometimes IgG also)	Serum reacts with rbcs only in the presence of drug; eluate non-reactive	
Drug Adsorption (DA) -Drug binds to RBC	IgG (sometimes C3 also)	React with drug-coated RBCs but not untreated RBCs- Ab to drug	
Autoantibodies -WAIHA	lgG (rarely C3 also) 11-36% of pts	React with normal RBCs in absence of drug	

## **Cold Agglutinin Disease**

- · Pathogenic antibodies are usually IgM
- Bind to red cells in the cooler extremities, then fix complement
- When red cells return to the warmer torso, IgM falls off
- Complement-coated red cells can be lysed directly within the vessel (intravascular hemolysis)
- Alternatively, complement-coated red cells can be engulfed by complement receptors on macrophages within the liver (extravascular hemolysis)

## **Cold Agglutinin Disease**



- In the cold, IgM can lead to red cell agglutination
- Red cells clumps cannot pass through microvasculature, leading to cyanosis and ischemia in extremities

John Lazarchick, ASH Image Bank 2011; 2011-1053

## Cold Agglutinin Disease Clinical features

- Can be associated with infection with either Mycoplasma or Mononucleosis
- Can also be idiopathic or associated with a Lymphoproliferative disease
  - Most commonly IgM monoclonal gammopathy
  - Lymphoma (may only be BM involvement)

## Cold Agglutinin DiseaseTreatment

- Treatment is to keep patient (especially the extremities) warm. Blood and IV fluids should be warmed.
- Immunosuppression with oral chemotherapy may be required
- · Steroids and splenectomy are usually ineffective.
- · Rituxan (PR in 20/27 patients)
- If Rituxan Refractory, can consider Eculizumab or Bortezomib

#### Treatment AIHA WAIHA CAD Drug-IHA 1st Line Treat if hemolysis Corticosteroids Avoid cold Treat secondary cause 2<sup>nd</sup> Line Folate Stop drugs Splenectomy Rituxan Chlorambucil 3<sup>rd</sup> Line Other Cytotoxic Plasmapheresis? Corticosteroids-Transfusion Transfuse – least Transfuse- I+ Transfuse Recommendation incompatible blood warmer

# Microangiopathic Hemolytic Anemia

- · Non-immune hemolytic anemia

  - NEGATIVE Coomb's
  - Prosthetic Valves, Heart valve induced, Pregnancy Associated Syndrome, HTN, Infections, Immune D/os, DIC
- Thrombotic Microangiopathy
- TTP, aHUS, HUS, Drug-Induced TMA